Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Inclusion Criteria: * Diagnosis of non-small cell lung cancer or Breast cancer, and adequate for carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin chemotherapy * Karnofsky Score ≥ 70 * Life Expectancy \> 3 months * Age: 18～70yrs. * Peripheral blood test: WBC≥3.5×106/mm3, PLT≥100×106/mm3, ANC≥1.5×106/mm3; Normal bone marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells. * Normal coagulation function, no evidences of hemorrhage tendency. * No exiting diseases or condition that may influence drug absorption, distribution, metabolism, and excretion. * Adequate liver, cardiac, kidney function. Indicators of liver function test ≤ 2.5ULN, Indicators of kidney function test ≤ 1ULN * Understand and voluntarily sign an informed consent form. Exclusion Criteria: * Pregnant or lactating females * Evidence of tumor metastasis in bone marrow * Lack insight due to tumor metastasis in the central nervous system * Prior bone marrow transplant or stem cell transplant * Infective symptom before enrollment into this study * Other malignancy history * Known hypersensitivity to any component of the drug(e.g. rh-G-CSF) that to be administered * Subject enrolled in any other investigational drug or device trial within 3 months of informed consent date * Drug abuser or alcoholist * Prior radiotherapy or expected to received radiotherapy * Unstable or uncontrolled cardiac or hypertension * Other conditions which in the opinion of the investigator preclude enrollment into the study